ZA202204943B - Crystalline forms of c-c chemokine receptor type 4 antagonist and uses thereof - Google Patents

Crystalline forms of c-c chemokine receptor type 4 antagonist and uses thereof

Info

Publication number
ZA202204943B
ZA202204943B ZA2022/04943A ZA202204943A ZA202204943B ZA 202204943 B ZA202204943 B ZA 202204943B ZA 2022/04943 A ZA2022/04943 A ZA 2022/04943A ZA 202204943 A ZA202204943 A ZA 202204943A ZA 202204943 B ZA202204943 B ZA 202204943B
Authority
ZA
South Africa
Prior art keywords
antagonist
chemokine receptor
receptor type
crystalline forms
same
Prior art date
Application number
ZA2022/04943A
Other languages
English (en)
Inventor
J Arnold David
Robles Omar
E Rudisill Duane
J Wustrow David
Zibinsky Mikhail
Karaborni Sami
Original Assignee
Rapt Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rapt Therapeutics Inc filed Critical Rapt Therapeutics Inc
Publication of ZA202204943B publication Critical patent/ZA202204943B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ZA2022/04943A 2019-11-13 2022-05-05 Crystalline forms of c-c chemokine receptor type 4 antagonist and uses thereof ZA202204943B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962935007P 2019-11-13 2019-11-13
PCT/US2020/060575 WO2021097339A1 (en) 2019-11-13 2020-11-13 Crystalline forms of c-c chemokine receptor type 4 antagonist and uses thereof

Publications (1)

Publication Number Publication Date
ZA202204943B true ZA202204943B (en) 2023-11-29

Family

ID=73856569

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2022/04943A ZA202204943B (en) 2019-11-13 2022-05-05 Crystalline forms of c-c chemokine receptor type 4 antagonist and uses thereof

Country Status (11)

Country Link
US (2) US12006318B2 (https=)
EP (1) EP4058456A1 (https=)
JP (2) JP2023501584A (https=)
KR (1) KR20220101099A (https=)
CN (1) CN114728972B (https=)
BR (1) BR112022009331A2 (https=)
CA (1) CA3158521A1 (https=)
IL (1) IL292755A (https=)
MX (1) MX2022005795A (https=)
WO (1) WO2021097339A1 (https=)
ZA (1) ZA202204943B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4058456A1 (en) 2019-11-13 2022-09-21 RAPT Therapeutics, Inc. Crystalline forms of c-c chemokine receptor type 4 antagonist and uses thereof
CN121002023A (zh) * 2023-04-24 2025-11-21 浙江华海药业股份有限公司 趋化因子受体调节剂制备方法和用途

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
DE3815221C2 (de) 1988-05-04 1995-06-29 Gradinger F Hermes Pharma Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen
JP2594486B2 (ja) 1991-01-15 1997-03-26 アルコン ラボラトリーズ インコーポレイテッド 局所的眼薬組成物
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
JP2008530211A (ja) * 2005-02-16 2008-08-07 メルク エンド カムパニー インコーポレーテッド ケモカイン受容体のモジュレーターとなる置換ピラゾール
TW201024298A (en) * 2008-09-23 2010-07-01 Palau Pharma Sa (R)-3-(N,N-dimethylamino)pyrrolidine derivatives
US8383812B2 (en) * 2009-10-13 2013-02-26 Bristol-Myers Squibb Company N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-3-(7-tert-butylpyrazolo[1,5-A][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide, a dual modulator of chemokine receptor activity, crystalline forms and processes
JP2013031931A (ja) * 2011-08-01 2013-02-14 Hitachi Koki Co Ltd 携帯式作業機
TW201311693A (zh) * 2011-09-02 2013-03-16 Kyowa Hakko Kirin Co Ltd 化學激活激素受體活性調節劑
AR096758A1 (es) * 2013-06-28 2016-02-03 Abbvie Inc Inhibidores cristalinos de bromodominios
AU2017302635B2 (en) * 2016-07-29 2021-09-16 Rapt Therapeutics, Inc. Chemokine receptor modulators and uses thereof
US10246462B2 (en) * 2016-09-09 2019-04-02 Flx Bio, Inc. Chemokine receptor modulators and uses thereof
JP2020533332A (ja) * 2017-09-12 2020-11-19 アルデア バイオサイエンシーズ インク． 障害を処置するためのｃｘｃｒ−２阻害剤
EP3706750A1 (en) 2017-11-06 2020-09-16 RAPT Therapeutics, Inc. Chemokine receptor modulators for treatment of epstein barr virus positive cancer
CN109796457B (zh) * 2019-03-28 2020-03-06 苏州国匡医药科技有限公司 一种2-(3-(氮杂环丁烷-3-基)哌啶-1-基)乙基-1-醇的制备方法及其应用
EP4058456A1 (en) 2019-11-13 2022-09-21 RAPT Therapeutics, Inc. Crystalline forms of c-c chemokine receptor type 4 antagonist and uses thereof

Also Published As

Publication number Publication date
CN114728972A (zh) 2022-07-08
JP2023501584A (ja) 2023-01-18
JP2026012675A (ja) 2026-01-27
US12006318B2 (en) 2024-06-11
AU2020383625A1 (en) 2022-05-05
KR20220101099A (ko) 2022-07-19
WO2021097339A1 (en) 2021-05-20
TW202132303A (zh) 2021-09-01
EP4058456A1 (en) 2022-09-21
MX2022005795A (es) 2022-06-08
IL292755A (en) 2022-07-01
CA3158521A1 (en) 2021-05-20
US20210139487A1 (en) 2021-05-13
US20240317768A1 (en) 2024-09-26
BR112022009331A2 (pt) 2022-08-09
CN114728972B (zh) 2024-12-10

Similar Documents

Publication Publication Date Title
MX2022006609A (es) Compuesto de quinazolina que contiene anillo espiro.
PH12020551870A1 (en) Tetracyclic heteroaryl compounds
MX2023006047A (es) Degradadores selectivos del receptor de estrogeno.
PH12021550048A1 (en) Selective estrogen receptor degraders.
PH12019500375A1 (en) A crystalline 19-nor c3, 3-disubstituted c21-n-pyrazolyl steroid
MX2023000835A (es) Formulaciones del esteroide c21-n-pirazolilo 19-nor c3,3-disustituido y metodos de uso de este.
EP4442695A3 (en) 19-homo, 3.alpha.-hydroxy-steroid-20-one compounds for treating cns disorders
PH12019500208A1 (en) Spiro-lactam nmda receptor modulators and methods of using same
ZA202204943B (en) Crystalline forms of c-c chemokine receptor type 4 antagonist and uses thereof
TW200635897A (en) Piperidine derivatives and their use as anti-inflammatory agents
MX2025010194A (es) Formas cristalinas de estado solido de un modulador selectivo de canales de potasio
MX418519B (es) Inhibidores selectivos de jak1
PH12020550253A1 (en) Bicyclic compounds for use as rip1 kinase inhibitors
ZA202305624B (en) Amorphous form of a complement component c5a receptor
PH12019501724A1 (en) Estrogen receptor modulators
WO2019194773A3 (en) The combination comprising linagliptin and metformin
MX2024013184A (es) Metodos y composiciones para tratar apnea del sue?o
PH12022551241A1 (en) Egfr inhibitors
MX2024000999A (es) Antagonista de molécula pequeña de lpa1.
EP4670791A3 (en) Compounds and compositions for treating conditions associated with lpa receptor activity
AU2016407426A1 (en) Triple combination of pure 5-HT6 receptor antagonists, Acetylcholinesterase inhibitors and NMDA receptor antagonist
PH12020551736A1 (en) The crystalline forms of a compound
WO2021011874A8 (en) Ghrh antagonists for use in a method of treating sarcoidosis
MX377517B (es) Combinacion triple de agonistas inversos del receptor de histamina 3, inhibidores de acetilcolinestearasa y antagonistas del receptor nmda.
EP4431114A3 (en) A pharmaceutical oral dosage form of q203